Analyzing the Decline of RYAN Stock Today

This morning we watched Ryan Specialty drop -5.2% to a price of $50.19 per share. The Large-Cap Specialty Insurance company is now trading -12.92% below its average target price of $57.63. Analysts have set target prices ranging from $52.0 to $63.0 per share for Ryan Specialty, and have given the stock an average rating of buy.

Ryan Specialty has an average level of shares sold short, at 6.6% of its total share float. The stock's short ratio (also called days to cover) is 7.23. The company's insiders own 15.25% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 84.3% of Ryan Specialty's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Ryan Specialty

Date Reported Holder Percentage Shares Value
2023-12-31 Kayne Anderson Rudnick Investment Management LLC 9% 10,136,768 $508,713,716
2023-12-31 Vanguard Group Inc 8% 9,397,569 $471,617,013
2023-12-31 Capital World Investors 5% 5,890,472 $295,613,345
2023-12-31 Zimmer Partners, Lp 4% 4,816,004 $241,691,167
2023-12-31 Blackrock Inc. 4% 4,403,879 $221,008,673
2023-12-31 Champlain Investment Partners, LLC 3% 3,857,827 $193,605,053
2023-12-31 Janus Henderson Group PLC 3% 3,103,916 $155,770,028
2023-12-31 Alliancebernstein L.P. 2% 2,900,977 $145,585,534
2023-12-31 Blair (William) & Company, L.L.C. 2% 2,700,316 $135,515,362
2023-12-31 T. Rowe Price Investment Management, Inc. 2% 2,019,648 $101,356,037
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.